The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement ...

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing ...

Approval was based on data from the Phase III NextCOVE trial, which demonstrated that mNEXSPIKE met non-inferiority criteria ...

The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

U.S. Department of Health and Human Services secretary Robert F. Kennedy, Jr announced on Tuesday that COVID vaccines will be ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

The new mRNA vaccine encodes the receptor-binding domain and the N-terminal domain of the SARS-CoV-2 spike protein ...

The US Food and Drug Administration has approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for individuals aged ...

The approval of the mNEXSPIKE vaccine comes less than a week after Health and Human Services Secretary, Robert F. Kennedy Jr. announced the COVID vaccine for healthy children and healthy pregnant ...